Scientific Reports (Oct 2022)

The nephroprotective action of Passiflora edulis in streptozotocin-induced diabetes

  • Ony Araújo Galdino,
  • Iago de Souza Gomes,
  • Renato Ferreira de Almeida Júnior,
  • Maria Imaculada Conceição Ferreira de Carvalho,
  • Bento João Abreu,
  • Marcela Abbott Galvão Ururahy,
  • Barbara Cabral,
  • Silvana Maria Zucolotto Langassner,
  • Karla Simone Costa de Souza,
  • Adriana Augusto de Rezende

DOI
https://doi.org/10.1038/s41598-022-21826-9
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 11

Abstract

Read online

Abstract In the present study, we aimed to evaluate the therapeutic effect of Passiflora edulis fruit peel aqueous (AFA) extract as an adjuvant to insulin to confer nephroprotection against streptozotocin-induced diabetes. Male Wistar rats were divided into four groups based on treatment received for 60 days: diabetic (DB), control (CTL), insulin (INS), and insulin + AFA extract (INS + AFA). mRNA and protein expression levels of podocyte (nephrin, podocin, and WT1) and tubular (megalin) proteins were measured in kidney tissue specimens and urine. Biochemical parameters and kidney histopathology were also examined. Herein, the INS + AFA group showed superior glycemic control, which resulted in the reduction of urinary albumin/creatinine ratio, maintenance of baseline levels of Nphs1, Nphs2, Wt1, and Lrp2 mRNA expression, prevention of protein loss from the kidney tissue into the urinary space, along with the maintenance of glomerular basement membrane thickness, hyalinization, glomerular and tubulointerstitial fibrosis at values approximating those of the CTL group and significantly lower than those in the DB group. Therefore, these results suggest that, as an anti-diabetic agent, the AFA extract adjuvant to insulin could reduce and potentially prevent diabetic kidney disease.